Targeting TET3 suppresses group 3 medulloblastoma stemness and progression via impairing hypomethylation of Otx2 super-enhancer
Authors:
Open Access
- 2 December 2025
- journal article
- Published by Elsevier in Cell Reports Medicine
- Vol. 6 (12) , 102474
Abstract
No abstract availableKeywords
Funding Information
- Chinese Academy of Medical Sciences
- Beijing Tian Tan Hospital, Capital Medical University
- Capital Medical University
This publication has 85 references indexed in Scilit:
- Spatiotemporal transcriptome atlas reveals the regional specification of the developing human brainCell, 2023
- TGF-β signaling in health and diseaseCell, 2023
- Mechanisms that regulate the activities of TET proteinsCellular and Molecular Life Sciences, 2022
- Integrated analysis of multimodal single-cell dataCell, 2021
- HDAC and MAPK/ERK Inhibitors Cooperate To Reduce Viability and Stemness in MedulloblastomaJournal of Molecular Neuroscience, 2020
- Characterization of a novel OTX2‐driven stem cell program in Group 3 and Group 4 medulloblastomaMolecular Oncology, 2018
- Intertumoral Heterogeneity within Medulloblastoma SubgroupsCancer Cell, 2017
- Biflavone Ginkgetin, a Novel Wnt Inhibitor, Suppresses the Growth of MedulloblastomaNatural Products and Bioprospecting, 2015
- Super-Enhancers in the Control of Cell Identity and DiseaseCell, 2013
- Tet3 CXXC Domain and Dioxygenase Activity Cooperatively Regulate Key Genes for Xenopus Eye and Neural DevelopmentCell, 2012